InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,222.68
(
0.16%
)
US TECH 100
17,652.00
(
0.06%
)
Dow Jones
39,512.84
(
0.32%
)
Brent Oil
82.59
(
0.00%
)
Bitcoin
60,815.03
(
0.03%
)
Post# of 251788
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 829
Posts 119609
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: dewophile post# 191752

Wednesday, 05/27/2015 12:30:51 PM

Wednesday, May 27, 2015 12:30:51 PM

Post# of 251788
ABBV’s PR pertains to only one trial (GIFT-1: https://clinicaltrials.gov/ct2/show/NCT02023099 ). The PR is confusing because there was a pre-specified subgroup analysis that constituted the primary endpoint and a separate randomized “safety control” group that consisted of non-cirrhotic patients (some of whom were treatment-experienced) whose treatment start was deferred by 12 weeks in order to perform the safety comparison to the main (immediate treatment) group. It’s this control group that had an SVR12 rate of 98% on an ITT basis.

If one merges the 95% (106/112) subgroup for the primary endpoint and the 98% (104/106) control group, the result is an SVR12 rate of 96.3% (210/218).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up